Signature(s)
Summary sheet
- Industry - Manufacturing
The project supports the company's research and development (R&D) investments in the field of antimicrobial resistance, in particular tuberculosis and nosocomial infections. By targeting hospital-acquired infections the project also addresses COVID-19, as such co-infections very often occur in hospitalised COVID-19 patients, leading to serious complications.
The project supports a clinical-stage biopharmaceutical company focusing on the treatment of anti-microbial resistance. The objective is to further advance the product, conduct additional clinical studies to validate the product and obtain regulatory approval. The proposed transaction will enable the Promoter to address one of the highest unmet medical needs for new treatments against life-threatening resistant bacterial infections and chronic inflammatory microbiome disorders. The project aims to increase the overall survival rate and quality of life of patients. In addition, it will encourage the growth and development of European scientific acumen.
The financing of this project addresses the failure in financial
markets for RDI - in this specific case in biopharmaceuticals. The failure
arises in part from limited access to and/or higher cost of financing due to information
asymmetries associated with the inherent uncertainty of RDI activities, and
resulting in high screening and monitoring costs. Other factors are the
misalignment of incentives, lack of collateral and/or lack of track record.
Through support from the Infectious Diseases
Finance Facility (IDFF), the operation addresses the need of a financially
underserved company operating in the sector of anti-microbial resistance linked
to high, unmet medical needs. The contribution to EU policy is therefore significant.
The EIB's contribution is notable on both the
financial and non-financial side. The funding provided under IDFF will
substantially enhance the financial resources available to the borrower to
execute its development plan and may crowd in further investors. Structuring
the financing as a venture debt operation (equity risk) is appropriate
given the borrower's stage of development and takes its cash flow profile into
account. Therefore, the EIB also provides an added value in terms of financial structuring
expertise, in addition to the technical contribution and advice.
The investment activities such as research, development and clinical studies are expected to be carried out in existing authorised facilities. Therefore, it would not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Full environmental details verified during the appraisal.
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services verified details during the project due diligence.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications